Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
U. Bjornsdottir, J.S. Jonsson, M. Jonsson, S.T. Sigurdardottir, G. Stratelis, G. Telg, M. Turesson, S. Gizurarson (Reykjavik, Gardabaer, Iceland; Södertälje, Stockholm, Sweden). Impact of reimbursement changes for fixed ICS/LABA combination treatment in Iceland. Eur Respir J 2012; 40: Suppl. 56, 1005

Member's Comments

No comment yet.

Related content which might interest you: Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Efficacy of montelukast as complementary therapy to fixed association ICS/LABA in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Analysis of the cost-effectiveness of monotherapy versus fixed dose combination treatment of asthma in Republic of Moldova Source: Annual Congress 2013 –Asthma at the bedside Year: 2013 Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy Source: Eur Respir J 2005; 26: Suppl. 49, 382s Year: 2005 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019 Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020 Year: 2021 Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002